论文部分内容阅读
目的 评价rhIL-2辅助治疗复治肺结核的临床疗效、辅助作用、适宜剂量、使用安全性及其不良反应。方法 选择复治肺结核,年龄18-65岁,非孕妇和授乳者,非HIV阳性者;无重要心、肝、肾疾患史;无精神病史及癫痫史者;Ⅱ型糖尿病患者空腹血糖控制良好(<150mg％或8.3mmol/L);对rhIL-2及其他生物制剂无过敏反应者作为受试者,按简单随机法分为试验组和对照组。试验组17例,其中男性12例,女性5例;对照组15例,其中男性12例,女性3例。病灶范围:试验组中占1-2个肺野4例,3-4个肺野4例,5-6个肺
Objective To evaluate the clinical efficacy, adjuvant effects, appropriate dosage, safety and adverse reactions of adjuvant rhIL-2 in the treatment of pulmonary tuberculosis. Methods: The patients with type II diabetes treated with retreatment of tuberculosis, aged 18-65 years old, non-pregnant and lactating, non-HIV positive persons, without important heart, liver and kidney disease history, without history of mental illness and epilepsy, <150mg% or 8.3mmol / L); rhIL-2 and other biological agents without allergic reaction as subjects, according to a simple randomized divided into experimental group and control group. The experimental group of 17 cases, including 12 males and 5 females; control group of 15 patients, including 12 males and 3 females. Lesions range: experimental group accounted for 1-2 lung fields in 4 cases, 3-4 lung fields in 4 cases, 5-6 lungs